PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Levomethadone→

Levomethadone PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
125-58-6
Molecular formula
C21H27NO
Molecular weight
309.4 g/mol
Drug class
Levorotatory opioidpotent mu-opioid receptor agonist
Mechanism of action
The active R-enantiomer of methadone. Activates mu-opioid receptors, reducing nociceptive neurotransmission and suppressing opioid withdrawal and craving in opioid dependence. It also inhibits NMDA receptor activity and monoamine reuptake to a lesser extent.
Indications / reported uses
  • Substitution maintenance treatment for opioid dependence within structured treatment programmes.
  • Treatment of severe pain when opioid analgesia is required, where the specific levomethadone product is authorised.

Sources: https://www.medicines.org.uk/emc/product/12795/smpc · https://www.ncbi.nlm.nih.gov/books/NBK537161/ · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Levomethadone PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levomethadone Permitted Daily Exposure (PDE) report (the Levomethadone PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levomethadone Occupational Exposure Limit (OEL) report (the Levomethadone OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.